Miravirsen
- Generic Name
- Miravirsen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1072874-90-8
- Unique Ingredient Identifier
- Q083AJW7VS
- Background
Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.
- Associated Conditions
- -
- Associated Therapies
- -
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01872936
- Locations
- 🇺🇸
Research Specialists of Texas, Houston, Texas, United States
🇺🇸The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇵🇷Fundacion de Investigacion de Diego, San Juan, Puerto Rico
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 38
- Registration Number
- NCT01200420
- Locations
- 🇵🇷
Fundacion de Investigation de Diego, San Juan, Puerto Rico
🇩🇪J.W. Goethe University Hospital, Frankfurt, Germany
🇺🇸Alamo Medical Research, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath